Luke Utley

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 444 citations · Full text

Medicine, Molecular Biology, Oncology +14

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo et al. · Cancer Cell · 2021 · 183 citations

Medicine, Cancer Biology, Oncology +14

Cellular localization of CD4 in the human placenta. Implications for maternal-to-fetal transmission of HIV.

Michael D. Lairmore, P S Cuthbert, Luke Utley et al. · The Journal of Immunology · 1993 · 64 citations · Full text

Life Sciences, Cell Biology, Immunology +13

Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects

Paul B. Eckburg, Troy Lister, Susannah M. Walpole et al. · Antimicrobial Agents and Chemotherapy · 2019 · 53 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

Boudewijn L. M. de Jonge, Grant K. Walkup, Sushmita D. Lahiri et al. · Antimicrobial Agents and Chemotherapy · 2013 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17